NDA 204168 · Abbvie
Fetzima
Levomilnacipran Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jul 25, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
73
24 Phase 3, 1 recruiting
FAERS reports
1,929
1,027 serious, 176 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 ) ] . FETZIMA is not approved for use in pediatric patients [see Use in Specific Populations ( 8.4 ) ] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ) . FETZIMA is not approved for use in pediatric patients ( 8.4 ).
What it is approved for
From the label in effect Apr 30, 2024.
FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults ( 1 ). Limitation of Use : FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established ( 1 ).
Mechanism: The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 24, 2023 Supplement 10 · Efficacy LetterLabel
- Oct 7, 2019 Supplement 6 · Efficacy LetterLabel
- Jul 25, 2013 Original approval · Type 2 - New Active Ingredient LetterLabelReview
4 products under this application
- FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 120MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 40MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 80MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
- FETZIMA · LEVOMILNACIPRAN HYDROCHLORIDE EQ 20MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Levomilnacipran" as an intervention, any sponsor and status, largest first.
- A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia SyndromePivotal-lookingCompleted
Pierre Fabre MedicamentIndustry
NCT00436033 · 1,429 participants · Start Feb 2006 · Primary completion Sep 2007
Drug: milnacipran; Placebo · For: Fibromyalgia Syndrome
Sites: Pardubice, Czechia; Frederiksberg, Denmark; Kuopio, Finland · 13 sites in all
- Study of Milnacipran for the Treatment of FibromyalgiaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00098124 · 1,200 participants · Start Nov 2004
Drug: milnacipran hydrochloride · For: Fibromyalgia
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 80 sites in all
- Study of Milnacipran for the Treatment of FibromyalgiaPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00314249 · 1,025 participants · Start Apr 2006 · Primary completion Jun 2008
Drug: Placebo; Milnacipran 100mg · For: Fibromyalgia
Sites: Tuscaloosa, Alabama; Fresno, California; Pismo Beach, California · 24 sites in all
- Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic PhenotypeStatus unknown
Samsung Medical CenterAcademic, hospital or other
NCT01352559 · 1,000 participants (planned) · Start Nov 2001 · Primary completion Mar 2007
Drug: responders; non-responders · For: Depression
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT01228357 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Depressive Symptoms
Sites: Kangnam, South Korea
Samsung Medical CenterAcademic, hospital or other
NCT00817375 · 1,000 participants (planned) · Start Feb 2003 · Primary completion Dec 2018
Drug: SSRI treated group; non-SSRI treated group · For: Depression; Adverse Reaction to Drug
Sites: Kangnam, South Korea
- Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT01085812 · 734 participants · Start Mar 2010 · Primary completion Oct 2011
Drug: Levomilnacipran ER; Placebo · For: Depression; Major Depressive Disorder
Sites: Beverly Hills, California; Encino, California; Garden Grove, California · 35 sites in all
- Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00969709 · 724 participants · Start Sep 2009 · Primary completion May 2011
Drug: Levomilnacipran ER; Levomilnacipran ER and 2 more · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Scottsdale, Arizona; Beverly Hills, California · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use350
- drug ineffective266
- pain225
- vomiting221
- memory impairment205
- hypoaesthesia198
- abdominal pain upper196
- paraesthesia192
- gastrooesophageal reflux disease185
- migraine183
- drug intolerance177
- epilepsy168
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 142 |
| 2015 | 214 |
| 2016 | 307 |
| 2017 | 224 |
| 2018 | 123 |
| 2019 | 174 |
| 2020 | 100 |
| 2021 | 112 |
| 2022 | 122 |
| 2023 | 111 |
| 2024 | 73 |
| 2025 | 158 |
| 2026 | 68 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fetzima (Levomilnacipran HCl)
2024 spending
$27.1M
Beneficiaries
5,792
39,287 claims
Per beneficiary
$4,676
$16.46 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,568,516 |
| 2021 | $29,762,191 |
| 2022 | $29,783,745 |
| 2023 | $29,339,819 |
| 2024 | $27,083,755 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis.
Pillinger T, Arumuham A, McCutcheon RA, et al. · Lancet 2025 · Network Meta-Analysis, Systematic Review
- Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Sakuma K, et al. · Mol Psychiatry 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.
Fava GA, Benasi G, Lucente M, et al. · Psychother Psychosom 2018 · Systematic Review
- Levomilnacipran: More of the Same?
Gautam M, Kaur M, Jagtap P, et al. · Prim Care Companion CNS Disord 2019 · Systematic Review
- Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis.
Oliva V, Lippi M, Paci R, et al. · Prog Neuropsychopharmacol Biol Psychiatry 2021 · Meta-Analysis, Systematic Review
- Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and doseߜresponse meta-analysis.
Wen S, Yan Y, Shao J, et al. · Transl Psychiatry 2025 · Meta-Analysis, Comparative Study
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.